Despite some wrinkles that remain to be ironed out, it is reasonable that the STING signaling pathway in hepatocytes is a potent promoter in the transition from NAFL to NASH, and targeting components in this signaling pathway turns out to be a promising therapy for individuals with NASH. Here, STING1 is linked to non-alcoholic fatty liver.